State Board of Administration of Florida Retirement System acquired a new stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Rating) during the second quarter, HoldingsChannel reports. The institutional investor acquired 12,453 shares of the company’s stock, valued at approximately $172,000.
A number of other large investors have also made changes to their positions in the stock. Nisa Investment Advisors LLC purchased a new position in IDEAYA Biosciences during the second quarter worth about $25,000. Point72 Hong Kong Ltd lifted its position in IDEAYA Biosciences by 363.7% during the first quarter. Point72 Hong Kong Ltd now owns 3,376 shares of the company’s stock worth $38,000 after buying an additional 2,648 shares during the period. Quantbot Technologies LP lifted its position in IDEAYA Biosciences by 90.5% during the first quarter. Quantbot Technologies LP now owns 4,000 shares of the company’s stock worth $44,000 after buying an additional 1,900 shares during the period. Amalgamated Bank purchased a new position in IDEAYA Biosciences during the first quarter worth about $48,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its position in IDEAYA Biosciences by 12.7% during the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 10,416 shares of the company’s stock worth $117,000 after buying an additional 1,171 shares during the period. Institutional investors and hedge funds own 93.25% of the company’s stock.
Analyst Upgrades and Downgrades
Several research firms recently weighed in on IDYA. Citigroup began coverage on IDEAYA Biosciences in a research report on Thursday, October 27th. They set a “buy” rating and a $26.00 target price on the stock. Oppenheimer increased their target price on IDEAYA Biosciences to $22.00 in a research report on Tuesday, September 6th. Guggenheim raised their price objective on IDEAYA Biosciences from $20.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, September 13th. Robert W. Baird raised their price objective on IDEAYA Biosciences from $18.00 to $24.00 and gave the stock an “outperform” rating in a report on Friday, November 18th. Finally, Stifel Nicolaus downgraded IDEAYA Biosciences from a “buy” rating to a “hold” rating and cut their price objective for the stock from $16.00 to $13.00 in a report on Monday, August 15th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, IDEAYA Biosciences currently has an average rating of “Moderate Buy” and a consensus price target of $28.14.
IDEAYA Biosciences Price Performance
IDEAYA Biosciences Profile
IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations.
- Get a free copy of the StockNews.com research report on IDEAYA Biosciences (IDYA)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- The Sell-Side Caps Gains In Dick’s Sporting Goods
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
- Want to Get a 10% Dividend Yield, Look Here
Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.